The Latest Analyst Ratings for Regenxbio
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 5 analysts have published their opinion on Regenxbio (NASDAQ:RGNX) stock. The average price target is $40.2, implying an upside from the current price of $18.95. The current average has decreased by 6.51% from the previous average price target of $43.00.
August 29, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have a bullish outlook on Regenxbio (NASDAQ:RGNX) with an average price target of $40.2, indicating potential upside.
The bullish outlook from analysts indicates a positive sentiment towards Regenxbio. The average price target of $40.2 is significantly higher than the current price of $18.95, suggesting potential upside. However, the decrease in the average price target from $43.00 to $40.2 may indicate some caution.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100